Sentien Biotechnologies is a clinical-stage company developing novel cell therapy approaches centered on its lead product, SBI-101. SBI-101 combines mesenchymal stromal cells (MSCs) within an approved blood-filtration device to allow controlled, sustained delivery of MSC secreted factors. The product is being tested to treat systemic inflammatory diseases and is being developed specifically for acute kidney injury (AKI). The company will use the funds from its recent financing to support the initial clinical development of SBI-101. Sentien is led by CEO Brian Miller and is based in Cambridge, MA. The company recently completed a Series A to advance its clinical program. Sentien Biotechnologies is a preclinical regenerative medicine company led by CEO Brian Miller focused on cell-based therapies for critical care. Its lead product, the Sentinel™, is a cell-containing dialysis device being developed to treat severe Acute Kidney Injury (AKI). The company intends to use the recently raised Series A funds to conduct a planned Phase I study of Sentinel. Sentien has received multiple SBIR awards from the U.S. National Institutes of Health, including a $3M Phase IIB grant to advance the technology into a Phase I clinical trial. In conjunction with the financing, two investor representatives will join Sentien’s board. The company is based in Medford, Massachusetts.

Total raised

$12M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2017